MedTrace Logo

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

NCT02420366 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 257

Last updated 2018-05-02

No results posted yet for this study

Summary

A multi-center, retrospective study of cases of serious bacterial infections including complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP), Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Acquired Bacterial Pneumonia (VABP), and/or bacteremia caused by Carbapenem-Resistant Enterobacteriaceae (CRE)

Conditions

  • Urinary Tract Infection, Complicated
  • Acute Pyelonephritis
  • Hospital Acquired Bacterial Pneumonia
  • Ventilator-associated Bacterial Pneumonia
  • Bacteremia

Sponsors & Collaborators

  • Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)

    lead INDUSTRY

Principal Investigators

  • Karen Fusaro · Sponsor GmbH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States
  • Greece
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02420366 on ClinicalTrials.gov